<DOC>
	<DOCNO>NCT00703573</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 2 dos S-777469 patient atopic dermatitis .</brief_summary>
	<brief_title>A Randomized , Double-Blind Study Evaluate Safety Efficacy 2 Doses S-777469 Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Screening Each patient must meet follow inclusion criterion screen enrolled singleblind period : Males females 18 65 year age time obtain write informed consent Patient understand study procedure agree participate study give write informed consent Patient agree allow digital photograph atopic dermatitis ( AD ) affect target area study Patient satisfies diagnostic criterion AD define criterion Hanifin Rajka ( Acta Derm Venereol.1980 ; 92 [ suppl ] :4447 ; J Am Acad Dermatol.2003 ; 49 [ 6 ] :10881095 ) , follow : Must 3 basic feature : Pruritis Typical morphology distribution : flexural lichenification linearity Chronic chronically relapse dermatitis Personal family history atopy ( asthma , allergic rhinitis , atopic dermatitis ) Plus 3 minor feature : Xerosis Ichthyosis/palmar hyperlinearity/keratosis pilaris Early age onset Tendency toward cutaneous infection ( esp . Staphylococcus aureus Herpes simplex ) /impaired cellmediated immunity Tendency toward nonspecific hand foot dermatitis Nipple eczema Cheilitis Recurrent conjunctivitis DennieMorgan infraorbital fold Keratoconus Anterior subcapsular cataract Orbital darken Facial pallor/facial erythema Pityriasis alba Anterior neck fold Itch sweat Intolerance wool lipid solvent Perifollicular accentuation Food intolerance Course influence environmental/emotional factor White dermographism/delayed blanch Immediate ( type I ) skin test reactivity ( Provide test result within one year Screening date . ) Elevated serum IgE . Patient negative laboratory result hepatitis B surface antigen IgG anti Hepatitis B core , hepatitis C virus antibody , human immunodeficiency virus ( HIV ) antibody test screen Serum creatinine blood urea nitrogen normal range screen Female patient child bear potential must negative pregnancy test screen Day14 Patient negative screen drug abuse screen Patient history clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal urological disease Patient liver function test result &gt; 1.25 upper limit normal NOTE : Under circumstance patient qualify regard liver function test ( alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] ) rescreened and/or requalified Patient QTc &gt; 450 ( male ) &gt; 470 ( female ) screen Randomization Patients eligible randomize doubleblind treatment must satisfy follow inclusion criterion : Patient follow end singleblind period ( Day 1 , randomization study drug ) : Physician 's Global Assessment ( PGA ) ≥ 2 ≤ 4 . The average score record even Day 3 morning Day 1 ( Baseline value ) Numerical Rating Scale ( NRS ) ≥ 4 . The average score record even Day 3 morning Day 1 ( Baseline value ) Behavior Rating Scale ( BRS ) ≥ 2 Patient negative laboratory result hepatitis B surface antigen , IgE antiHepatitis B core , hepatitis C virus antibody , HIV antibody test screen Female patient child bear potential must negative pregnancy test screening , singleblind period ( Day14 ) baseline ( Day 1 ) Serum creatinine blood urea nitrogen normal range screen Patient negative screen drug abuse screen singleblind ( Day14 ) Use adequate birth control men woman , reproductive potential sexually active . Adequate birth control define agreement consistently practice effective accept method contraception throughout duration study 2 week last dose study drug For female , adequate birth control method define : hormonal contraceptive , intrauterine device double barrier contraception , i.e. , condom + diaphragm , condom diaphragm + spermicidal gel foam For male adequate birth control method define double barrier contraception , i.e. , condom + diaphragm , condom diaphragm + spermicidal gel foam For female , menopause define one year without menses ; question , folliclestimulating hormone &gt; 40 U/ml must document . Hysterectomy , bilateral oophorectomy , bilateral tubal ligation must document , applicable Patient use treatment AD prior Day 1 , use following time period : Systemic ( inhale , oral , suppository immediate release injectable , depot sustainedrelease injectable ) corticosteroid , cytostatic drug , immunosuppressant drug : 5 week prior Day 1 Topical immunosuppressant drug : 4 week prior Day 1 Phototherapy , specific desensitization therapy , nonspecific diseasemodulating therapy elimination diet therapy : 4 week prior Day 1 Any drug know inhibitor inducer Cytochrome P450 isozyme cytochrome CYP2C9 : 2 week prior Day 1 Systemic antibiotic : 4 week prior Day 1 Topical steroid tar preparation : 2 week prior Day 1 Antihistamines , histamineadded γglobulin preparation , desensitization therapy , nonspecific diseasemodifying therapy : 2 week prior Day 1 Herbal preparation , cosmetic emollient preparation issue screen singleblind period : 2 week prior Day 1 . Use cosmetic makeup allow Acetaminophen , acetaminophencontaining product , nonsteroidal antiinflammatories : 2 week prior Day 1 Any investigational drug device within 8 week prior Day 1 Patient willing completely avoid use prescription nonprescription treatment AD , include overthecounter drug topical preparation , topical emollient preparation provide study site screen period thereafter , need . Use hormone replacement therapy ( postmenopausal female ) and/or use hormonal contraceptive ( ) , intrauterine device , double barrier contraception , i.e. , condom + diaphragm , condom diaphragm + spermicidal gel foam allow . Use topical antibiotic allow study Patients satisfy follow exclusion criterion eligible enrollment doubleblind treatment period : Patient age legal consent , mentally legally incapacitate and/or significant emotional problem time study entry Patient active dermatologic condition AD may confound diagnosis evaluation AD , scabies , allergic contact dermatitis , seborrheic dermatitis , cutaneous lymphoma , psoriasis Patient history malignancy remission &gt; 5 year , exception cutaneous basal cell carcinoma cutaneous squamous cell carcinoma Presence comorbid condition would preclude participation study , include : Immune compromise state , include recent chemotherapy , immunotherapy , organ transplant History clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal urological disease Signs symptoms eczema herpeticum within precede 12 month cellulitis within precede 3 month Positive result HIV infection screen History clinical manifestation significant neurological ( e.g. , epilepsy ) psychiatric disorder ( e.g. , history suicide attempt ; history psychiatric episode result hospitalization ) An active intercurrent infection History clinically significant hypersensitivity , anaphylaxis , allergy drug compound , result severe adverse event Liver function test ( ALT , AST ) &gt; 1.25 time upper limit normal Screening . ( refer Covance Lab Manual reference range ) Note : Under circumstance patient qualify regard liver function test ( ALT and/or AST ) rescreened and/or requalified Patient acute chronic condition prior therapy , opinion Investigator , would limit patient 's ability complete and/or participate clinical study otherwise would make patient unsuitable study Patient history drug abuse within 1 year prior Day 1 Patient consumes excess amount alcohol , define exceed average 14 drinks/week ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor , combination ) within 2 month prior Day 14 ( begin singleblind period ) unwilling comply restrict use alcohol ( define , 14 drinks/week ) screening , throughout study , study completion ( followup visit ) . Patient us prohibit concomitant medication time study Patient pregnant lactate intend become pregnant , case male patient , intend father child study period 2 week last dose study medication Patient poor peripheral venous access may limit blood sample clinical laboratory pharmacokinetic analysis Patient participate investigational study drug device trial receipt investigational study drug device occur within 8 week prior Day 1 Prior exposure S777469 Any reason , opinion Investigator , interfere ability patient participate complete trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>